Yoon-Jae Cho, M.D., Ph.D.
Affiliations: | Pediatric Neurology | Oregon Health and Science University, Portland, OR |
Area:
Neuro-oncologyGoogle:
"Yoon-Jae Cho"Mean distance: 15.51 (cluster 11) | S | N | B | C | P |
Parents
Sign in to add mentorScott L. Pomeroy | post-doc | 2007-2010 | Harvard Medical School/Children's Hospital |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Garancher A, Suzuki H, Haricharan S, et al. (2020) Abstract IA11: Overcoming immune evasion in pediatric brain tumors Cancer Research. 80 |
Garancher A, Suzuki H, Haricharan S, et al. (2019) IMMU-03. TUMOR NECROSIS FACTOR OVERCOMES IMMUNE EVASION IN P53-MUTANT MEDULLOBLASTOMA Neuro-Oncology. 21: ii93-ii93 |
Bakhshinyan D, Venugopal C, Adile AA, et al. (2018) BMI1 is a therapeutic target in recurrent medulloblastoma. Oncogene |
Kahn SA, Wang X, Nitta RT, et al. (2018) Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma. Nature Communications. 9: 4121 |
Purzner T, Purzner J, Buckstaff T, et al. (2018) Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma. Science Signaling. 11 |
Nitta R, Bolin SM, Nwagbo G, et al. (2018) Abstract LB-322: Casein kinase 2 is a major regulator of medulloblastoma growth Cancer Research. 78 |
Henderson JJ, Wagner JP, Hofmann NE, et al. (2017) Functional validation of the oncogenic cooperativity and targeting potential of tuberous sclerosis mutation in medulloblastoma using a MYC-amplified model cell line. Pediatric Blood & Cancer |
Gholamin S, Mitra SS, Feroze AH, et al. (2017) Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Science Translational Medicine. 9 |
Henderson J, Cho H, Davare M, et al. (2017) PDTM-36. FUNCTIONAL GENOMIC ANALYSIS OF MYC-AMPLIFIED MEDULLOBLASTOMA NOMINATES THE TGFB PATHWAY AS A CLINICALLY VIABLE TARGET Neuro-Oncology. 19: vi197-vi197 |
Phoenix TN, Patmore DM, Boop S, et al. (2016) Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. Cancer Cell |